Hims & Hers Health (HIMS) reported Q3 earnings late Monday of $0.32 per diluted share, swinging from a loss of $0.04 a year earlier.
Analysts polled by Capital IQ expected EPS of $0.05.
Revenue in the quarter ended Sept. 30 was $401.6 million, up from $226.7 million a year earlier.
Analysts surveyed by Capital IQ expected $382.8 million.
The company expects Q4 revenue of between $465 million and $470 million. Analysts expect $421.1 million.
For full-year 2024, it now expects revenue between $1.46 billion and $1.47 billion. The company was previously looking at full-year revenue of $1.37 billion to $1.40 billion. Analysts expect $1.4 billion.
Price: 20.50, Change: +0.14, Percent Change: +0.69
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.